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The Fanconi anemia (FA) protein FANCF is an essen-
tial component of a nuclear core complex that protects
the genome against chromosomal instability, but the
specific function of FANCF is still poorly understood.
Based upon the homology between human and Xenopus
laevis FANCF, we carried out an extensive mutagenesis
study to examine which domains are functionally impor-
tant and to gain more insight into the function of
FANCF. In contrast to previous suggestions, we show
that FANCF does not have a ROM-like function. We
found that the C terminus of FANCF interacts directly
with FANCG and allows the assembly of other FA pro-
teins into a stable complex. The N terminus appears to
stabilize the interaction with FANCA and FANCG and is
essential for the binding of the FANCC/FANCE subcom-
plex. We identified several important amino acids in this
N-terminal region but, surprisingly, many amino acid
changes failed to affect the function of the FANCF pro-
tein. Our data demonstrate that FANCF acts as a flexible
adaptor protein that plays a key role in the proper as-
sembly of the FA core complex.
Fanconi anemia (FA)1 is an autosomal recessive chromo-
somal instability syndrome. The clinical phenotype of FA pa-
tients is characterized by congenital abnormalities, progressive
bone marrow failure, and a predisposition to cancer; particu-
larly acute myeloid leukemia and squamous cell carcinoma (1,
2). The spontaneous cytogenetic aberrations specific for FA
cells are exacerbated upon treatment with DNA cross-linking
agents, such as mitomycin C (MMC) and diepoxybutane, which
suggests a DNA maintenance defect particularly in the han-
dling of cross-link damage.
To date, somatic cell fusion studies have demonstrated 11 FA
complementation groups (A-C, D1, D2, E-G, I, J, L) (3) and
eight of the FA-associated genes have been identified: FANCA,
FANCC, FANCD1/BRCA2, FANCD2, FANCE, FANCF,
FANCG, and FANCL (4–12). These FA genes encode orphan
proteins and no functional domains have been found in their
primary amino acid sequences, except for a RING finger in
FANCL (10) and multiple TPR motifs in FANCG (13). In
FANCF a region with homology to RNA-binding protein ROM
has been suggested to provide a clue for its function (5).
FANCA, FANCC, FANCE, FANCF, FANCG, and FANCL
assemble in a nuclear core complex (10, 14–17), in which
FANCG binds directly to FANCA and FANCF and FANCC
binds directly to FANCE (15, 16). The nuclear core complex is
essential for the monoubiquitination of FANCD2 (18) and this
modified form of FANCD2 colocalizes with BRCA1, RAD51
(19), and PCNA (20) in foci that also contain other DNA repair
proteins. Nevertheless, it is still unknown how monoubiquiti-
nated FANCD2 is involved in DNA repair and MMC resistance.
Recently, biallelic mutations in BRCA2 have been found in cell
lines derived from FA-D1 patients, adding BRCA2 to the list of
FA proteins (8). The BRCA proteins are known to be involved in
a multitude of biological functions including DNA repair, re-
combination, cell cycle control, and transcription (21). BRCA2
appears to be directly linked to the repair of double-stranded
breaks (DSBs) by homologous recombination (22). FANCD2
has also been identified as a target of the ataxia telangiectasia
(AT) signaling pathway (23) and seems to be functionally con-
nected to the RAD50/MRE11/NBS1 (RMN) protein complex
(24, 25), which plays an important role in the repair of DSBs
(26). Taken together, these data suggest that the FA proteins
serve to maintain genomic stability and integrity, in concert
with other protein complexes.
FANCF plays an important role in the FA pathway and its
functional disruption seems to be involved in specific types of
cancer, as suggested from the hypermethylation of the FANCF
promoter in a subset of ovarian, oral, lung, and cervical cancers
(27–29). Nevertheless, the function of FANCF is still poorly
understood. Patient-derived mutant forms of FA proteins and
structure/function analysis of FANCA, FANCC, and FANCG
have been informative in finding important functional residues
(30–34), but for FANCF this information is lacking, since none
of the FA-F patients have missense mutations that could pro-
vide insight into its function (5). For this reason, we started a
site-directed mutagenesis study to obtain more information
about functional domains in the FANCF protein. Because such
domains are expected to be relatively conserved during evolu-
tion, we searched for FANCF homologs in lower vertebrates
that might highlight important residues in FANCF. We found
a X. laevis homolog of FANCF (xFANCF), which has a rela-
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tively low overall homology with human FANCF. However, two
relatively conserved regions were located at the N and C ter-
minus. Based upon this conservation we generated a large
panel of FANCF mutants and identified several functionally
important amino acids and domains in FANCF. This study
reveals that FANCF is an adaptor protein that plays a key role
in the proper assembly of the FA core complex. To be able to
perform this function the N terminus of FANCF interacts with
the FANCC/FANCE subcomplex, whereas the C terminus
binds to the FANCA/FANCG subcomplex.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection—Epstein-Barr virus (EBV)-trans-
formed lymphoblasts were cultured in RPMI 1640 media supplemented
with 1 mM glutamine (Invitrogen) and 10% fetal calf serum (Invitrogen).
Selection medium to obtain stable cell lines also contained hygromycin
B (100 g/ml; Roche Applied Science). For stable expression lympho-
blastoid cell lines were transfected by electroporation using an ECM830
electrosquareporator (BTX, San Diego, CA). The MMC-induced growth
inhibition assays were performed as previously described (35–36).
Generation of FANCF Mutant Constructs—The FANCF mutant con-
structs were generated by PCR with oligonucleotides encoding the
amino acid substitutions or deleted regions of the FANCF sequence. We
used as a template the FANCF cDNA clone 10 obtained by expression
cloning (5). The FANCF mutant R47AF48A was made using the
QuikChange site-directed mutagenesis kit (Stratagene) according to
the manufacturer’s instructions. All FANCF mutants have been ana-
lyzed by sequencing to confirm that the desired changes had occurred
and to exclude the presence of other PCR derived alterations. The
mutants were subcloned into the expression vector pCEP4 (Invitrogen)
and transfected in FA-F lymphoblasts, EUFA698. FANCF mutants
1–15del, and delC31, and wild-type FANCF-FLAG were also subcloned
into the expression vector pIRESneo (Clontech, Palo Alto, CA) to gen-
erate stable cell lines. Expression of the mutant proteins in the stable
cell lines was confirmed by immunoprecipitation and immunoblotting
with FANCF-specific antibodies.
Sequence Analysis—FANCF mutants and the X. laevis FANCF IM-
AGE clone 3200942 (obtained from HGMP Resource Centre, Cam-
bridge, UK), were subcloned in pBluescript SK- and were sequenced
with CY5.5-labeled T7 and T3 primers using a Thermo Sequenase
primer cycle sequencing kit (Amersham Biosciences). Products were
analyzed on a Visible Genetics automatic DNA sequencer (Visible Ge-
netics Inc, Toronto, Ontario, Canada).
Yeast Two-hybrid Analysis—The MATCHMAKER Two-Hybrid Sys-
tem 3 (Clontech) was used according to the manufacturer’s instructions
as previously described (15). In brief, bait and prey constructs were
sequentially transformed into AH109 yeast cells and selected on -Trp-
Leu-His-Ade medium. The resulting colonies were tested for -galacto-
sidase expression with 5-bromo-4-chloro-3-indolyl--D-galactopyrano-
side (X-gal). To confirm interactions a yeast-mating assay was used
where constructs were transformed separately into two different yeast
strains and mating cultures plated onto selection medium as above. All
constructs were tested for self-activation against a series of control
plasmids and expression of the mutant proteins was verified by
immunoblotting.
Mammalian Two- and Three-hybrid Analysis—Human embryonic
kidney cells 293, either untransfected or stably transfected with wild
type or mutant (L554P) FANCC were plated onto 6-well plates. After
48 h, the cells were transiently transfected with FANCE cDNA fused to
the GAL-4 activation domain (pVP16; Clontech) and the indicated
FANCF constructs fused in-frame to the GAL4 DNA binding domain
(pM; Clontech) (1 g of each), together with a GAL4-driven reporter
plasmid (G5E1bLUC, 0.2 g). The luciferase activity was monitored
after 24 h using a Dual-Luciferase Reporter Assay System (Promega)
and a single tube luminometer (DLReady, Berthold Detection Systems),
according to the manufacturer’s instructions. All GAL4 constructs were
sequenced to confirm the correct reading frame and each experimental
data set was performed in triplicate to overcome the variability inher-
ent to transfections. Transient expression of the FANCF constructs and
stable expression of FANCC were confirmed by immunoblotting with
FANCF and FANCC-specific antisera.
Subcellular Fractionation, Immunoprecipitation, and Immunoblot-
ting—Nuclear and cytoplasmic fractions of the lymphoblastoid cell lines
were obtained as described previously (17). Cell extracts (107 cells)
were prepared in lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl and 1%
Nonidet P-40 supplemented with protease inhibitors) and subjected to
immunoprecipitation using the indicated antibodies, as previously de-
scribed (14). Anti-FLAG M2 affinity gel (Sigma) was used to immuno-
precipitate FLAG-tagged proteins. Immunoprecipitates or lysates were
then separated on 8% SDS-polyacrylamide gels, transferred to polyvi-
nylidene difluoride membranes, and specific proteins were detected by
immunoblotting with the indicated antibodies.
RESULTS
Homology between the Human and Xenopus FANCF Pro-
teins—Since functionally important amino acids are well con-
served between species, we searched several databases for
FANCF homologs to obtain clues about functional domains. In
the NCBI data base an IMAGE clone (3200942) was found,
which represented the full-length Xenopus laevis homolog of
FANCF (xFANCF). The cDNA was sequenced, and the pre-
dicted protein was aligned with the human FANCF sequence
(Fig. 1). The overall homology between both sequences ap-
peared to be limited (27% identity, 49% similarity) and dis-
persed over the whole molecule. However, relatively high se-
quence conservation was found in both the N- and C-terminal
regions of the protein. To test if this limited homology was
sufficient to function in a human background, FLAG-tagged
xFANCF was transfected into a cell line from an FA-F patient
(EUFA698). Unlike the human protein, xFANCF was unable to
complement the MMC hypersensitivity of the cells, despite of
its proper expression (Fig. 2). The untagged xFANCF protein
was also unable to complement the MMC defect in FA-F cells
(data not shown), indicating that xFANCF is not able to restore
the human FA pathway.
The FANCF Region Homologous to ROM Is Not Conserved
and Not Essential for Function—FANCF was first described as
FIG. 1. Sequence alignment of hu-
man and X. laevis FANCF proteins.
Alignments were made with BoxShade.
The black-shaded residues are identical,
and the gray-shaded residues are similar
between human and Xenopus FANCF.
The box shows the region homologous to
the prokaryotic RNA-binding protein
ROM. The asterisks point out the amino
acids essential for RNA binding activity
in ROM, and the triangles indicate the
amino acids that were mutated in the
ROM homologous region. The N- and C-
terminal deletion mutants that were gen-
erated are also indicated. GenBankTM ac-
cession number for xFANCF: AY547288.
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a novel protein with homology to the prokaryotic RNA-binding
protein ROM (5). The sequence alignment shows that the
FANCF region homologous to ROM (amino acids 145–209) is
not well conserved between human and Xenopus FANCF. Fur-
thermore, the amino acids essential for RNA binding (Gln-166
and Arg-173) are not identical in xFANCF. To further study
this region, Arg-173 was changed into alanine and the mutant
protein was tested for its ability to complement the MMC
hypersensitivity of FA-F cells. Although this amino acid change
abolished RNA binding in ROM (37), it did not have an effect on
the activity of FANCF (Fig. 3). Similarly, FANCF mutants of
the glutamic acid that is identical between hFANCF and ROM
(E172A and E172P) were still functional. These data suggest
that the FANCF region homologous to ROM is unlikely to have
an essential ROM-like function.
The C Terminus of FANCF Binds Directly to FANCG—Rel-
atively high sequence conservation was found in the C termi-
nus of FANCF (Fig. 1). To study the function of this conserved
region, several deletion constructs were generated and tested
for their ability to complement the MMC hypersensitive phe-
notype of FA-F cells. Surprisingly, FANCF mutants with C-
terminal deletions of 23, 31, or 40 amino acids all comple-
mented the MMC hypersensitivity of FA-F cells (Fig. 4A),
although the survival curves were slightly shifted toward a
higher sensitivity when more amino acids were deleted. Con-
sistent with the notion that FANCD2 monoubiquitination is
required for MMC resistance, FA-F cells transfected with the
delC31 mutant expressed monoubiquitinated FANCD2 under
normal conditions and after MMC treatment (data not shown).
Co-immunoprecipitation experiments showed that the FANCF
deletion mutants had a reduced interaction with FANCA and
FANCG when compared with wild-type FANCF (Fig. 4B). De-
letion of 31 or 40 amino acids completely abolished the inter-
action in this assay. Since FANCF has been shown to interact
directly with FANCG (15, 38), we tested the interaction be-
tween FANCG and the deletion mutants in a yeast two-hybrid
assay. In both co-transformation and mating experiments the
mutants with a deletion of 31 or 40 amino acids had a strongly
reduced FANCG binding (Table I). These results demonstrate
that the last 31–40 amino acids in the C terminus of FANCF
are important for the direct interaction with FANCG. By in-
terfering with the binding to FANCG, the interaction with
FANCA is also disturbed, indicating that the C terminus of
FANCF is binding the FANCA/FANCG subcomplex through
FANCG.
The N Terminus of FANCF Is Involved in Binding of the
FANCC/FANCE Subcomplex—We next evaluated the function
of a deletion mutant that lacked the highly conserved first 15
amino acids of FANCF. The mutant FANCF protein was not
able to complement the MMC hypersensitivity of FA-F cells,
despite its proper expression and nuclear localization (Fig. 5).
Although this mutant protein interacted with FANCA and
FANCG, the interaction was weak compared with that of wild-
type FANCF (Figs. 4B and 8B).
Unlike wild-type FANCF, which can be immunoprecipitated
in a complex with FANCE, we did not detect any FANCE in a
complex with the N-terminal deletion mutant of FANCF using
antisera against FANCE (Fig. 6A). Furthermore, the mutant
protein did not restore the interaction among FANCE, FANCA,
and FANCG that is observed in wild-type cells. Similarly, the
C-terminal deletion mutant lacking the last 31 amino acids was
unable to bind FANCE and could not form a stable FA complex
(Fig. 6A). In a reciprocal experiment, FANCC and FANCE did
not co-immunoprecipitate with the N-terminal deletion mutant
(Fig. 6B). Taken together, these results indicate that the N
terminus of FANCF is essential for its function and is involved
in the binding of FANCC and FANCE.
An important question for functional studies is how these
FIG. 2. Xenopus FANCF protein is not functional in human
cells. A, MMC hypersensitive phenotype of the FA-F lymphoblastoid
cell line EUFA698 is corrected by stable transfection with cDNA encod-
ing human FANCF, but not with cDNA encoding Xenopus FANCF. B,
expression of FLAG-tagged human and Xenopus FANCF proteins in
EUFA698 cells. Cell lysates of the indicated cell lines were immuno-
precipitated with anti-FLAG antibody and immunoblotted with rabbit
FANCA antiserum 89 and anti-FLAG.
FIG. 3. The FANCF region homologous to ROM is not required
to correct the MMC hypersensitivity of FA-F cells. Sequence
alignment showing the homology between human FANCF and the
prokaryotic RNA-binding protein ROM. The asterisks point out the
amino acids essential for RNA binding activity in ROM, and the arrows
indicate the amino acids that were mutated. The MMC hypersensitive
phenotype of the FA-F lymphoblastoid cell line EUFA698 is corrected to
wild-type levels by stable transfection with cDNAs encoding the
FANCF mutants R173A, E172A, and E172P. Lymphoblastoid cell line
HSC93 is shown as a wild-type control.
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proteins associate in the core complex. Previously, no direct
interaction between FANCF and FANCC or FANCE has been
found in yeast two-hybrid assays (15, 38), suggesting that the
association with FANCC and FANCE is indirect. We investi-
gated these interactions in a mammalian two-hybrid assay and
also in this assay FANCF did not interact with FANCC or
FANCE (Fig. 6C), whereas an interaction between FANCC and
FANCE was observed. We then sought to determine if the N
terminus of FANCF might be involved in the binding of this
FANCC/FANCE subcomplex, using a mammalian three-hybrid
(M3H) system, with 293 cells stably overexpressing FANCC. In
this assay, we observed a strong induction of the reporter gene
when FANCF was cotransfected with FANCE (Fig. 6D), indi-
cating that FANCC acts as a molecular bridge between FANCF
and FANCE. As a control experiment, we used a 293 cell line
stably overexpressing FANCC mutant L554P, which is defec-
tive in binding FANCE (16, 38) and found no interaction be-
tween FANCF and FANCE (data not shown). To further extend
these observations, we tested the FANCF N- and C-terminal
deletion mutants in the M3H assay. In agreement with our
co-immunoprecipitation experiments, the FANCF mutant
1–15del completely failed to interact with FANCE, whereas the
FANCF mutant delC31 had a reduced interaction (Fig. 6D).
Collectively, these observations indicate that the first 15 amino
acids of FANCF are essential for the direct binding of the
FANCC/FANCE subcomplex. Furthermore, they demonstrate
that this interaction also partially depends on the C-terminal
part of the FANCF protein.
The N Terminus of FANCF Contains Several Residues Es-
sential for Its Function—Several missense mutants were gen-
erated to delineate amino acids in the N-terminal region of
FANCF essential for its interaction with the other FA proteins
and for its ability to complement the MMC defect in FA-F cells
(see Table II). Secondary structure prediction programs indi-
cate that the first 15 amino acids of human FANCF form an
FIG. 4. Deletion mutants of the C terminus of FANCF are func-
tional, but do not stably interact with FANCA and FANCG. A,
MMC hypersensitive phenotype of the FA-F cell line EUFA698 is cor-
rected after stable transfection with FANCF mutants that lack 23
(FdelC23), 31 (FdelC31), or 40 (FdelC40) amino acids of the C terminus.
Lymphoblastoid cell line HSC93 is shown as a wild-type control. B, cell
lysates from wild-type (HSC93), FA-F (EUFA698), and the indicated
stably transfected FA-F lymphoblasts were immunoprecipitated with
guinea pig anti-FANCF1–245 and immunoblotted with rabbit FANCA
antiserum 89, rabbit anti-FANCG83–622 and rabbit anti-FANCF1–374 to
show precipitated FANCA, FANCG and FANCF. The asterisks indicate
the position of FANCG.
TABLE I
Yeast two-hybrid data of FANCG and the C-terminal deletion
mutants of FANCF
DNA-BDa: pGBK-FANCG
DNA-ADb: pGAD-FANCF-
delC
Reporter
gene
activation
Co-transformations 1 and 2
FANCF-delC23 
FANCF-delC31 
FANCF-delC40 
Mating assays 1 and 2
FANCF-delC23 
FANCF-delC31 
FANCF-delC40 -
a BD, GAL4 binding-domain.
b AD, GAL4 activation-domain.
FIG. 5. Deletion of amino acids 1–15 inactivates FANCF, with-
out affecting the nuclear localization. A, MMC hypersensitive phe-
notype of the FA-F cell line EUFA698 is not corrected after stable
transfection of cDNA encoding a FANCF mutant from which the first
N-terminal 15 amino acids were deleted (F1–15del). Lymphoblastoid
cell line HSC93 is shown as a wild-type control. B, subcellular localiza-
tion of FANCF mutant F1–15del. Equal amounts of cytoplasmic (C) and
nuclear (N) proteins from wild-type (HSC93), FA-F (EUFA698) lympho-
blasts and EUFA698 stably transfected with FANCF mutant F1–15del
(EUFA698 F1–15del) were immunoprecipitated with anti-FANCF1–245.
Precipitated FANCF was visualized by immunoblotting with rabbit
anti-FANCF1–374. Topoisomerase II (TOP2) and -tubulin (TUB)
antibodies were used as nuclear and cytoplasmic markers, respectively.
FANCF Is a Flexible Adaptor Protein39424
 at Vrije Universiteit, Medical Library, on December 21, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
amphipathic -helix (Fig. 7), with a strong negative charge at
one side of the helix (Glu-2, Asp-9, and Glu-13). In the Xenopus
homolog a similar structure was predicted, with Glu-6, Asp-9,
and Glu-13 at the negative side of the helix.
These negatively charged amino acids were either changed
into alanines (E2AD9AE13A) or replaced by positively
charged lysines (E2KD9KE13K) and the mutants were
tested for their ability to complement the MMC hypersen-
sitivity of FA-F cells, and for their ability to interact with
FANCA. Both mutants were able to complement the MMC
defect (Fig. 8A), but like the N-terminal deletion mutant, the
E2KD9KE13K mutant appeared to have a reduced interac-
tion with FANCA (Fig. 8B). Since the C terminus of FANCF is
also involved in the interaction with FANCA (Fig. 4B), we
tested mutants with a combination of mutation and deletions to
determine if the N- and C-terminal conserved regions of
FANCF act in concert. When the last 23 C-terminal amino
acids were removed, the E2AD9AE13A mutant was still
biologically active, whereas the E2KD9KE13K mutant be-
came inactive (Fig. 8C). We then removed 31 C-terminal amino
acids of these mutants and found that this completely abol-
ished the activity of both mutants (Fig. 8D). Thus, reversing
the charges of the residues in the FANCF -helix is more
disruptive than neutralizing the positively charged residues.
We infer that the three negatively charged amino acids in the
first N-terminal -helix of FANCF are functionally important
and that FANCF has partially interdependent functional ter-
minal domains.
The hydrophobic side of the N-terminal -helix contains
three conserved leucines (Leu-5, Leu-8, and Leu-15). When
these leucines were replaced by alanines, the mutant protein
was functional in an MMC test (Fig. 9A). However, this mu-
tant was totally inactivated upon removal of the 31 C-ter-
minal amino acids (Fig. 9A), hinting that the conservation at
the hydrophobic side of the helix is of functional significance.
We then examined the ability of the FANCF mutant
L5AL8AL15A (with an intact C terminus) to interact with
the FANCC/FANCE subcomplex in the M3H assay and found
that this mutant failed to activate transcription of the lucifer-
ase reporter gene (Fig. 9C). These results suggest that the
three leucines residues are involved in the direct binding of the
FANCC/FANCE subcomplex.
We further investigated N-terminal mutants, in which combi-
nations of the conserved arginine (Arg-10) or phenylalanine (Phe-
11) residues were modified. All the single mutants were able to
complement the MMC hypersensitivity of FA-F cells (Table II)
and displayed a normal interaction with FANCA (Fig. 8B). These
mutants were still functional when the C-terminal 31 amino
acids were removed (Table II). However, a double mutant in
which both Arg-10 and Phe-11 were changed into alanine
FIG. 6. Interaction of FANCF mutants with the FANCC/FANCE subcomplex. A, cell lysates from wild-type (HSC93), FA-F (EUFA698)
lymphoblasts and FA-F cells stably transfected with the indicated FANCF mutants were immunoprecipitated with anti-FANCE and immuno-
blotted with anti-FANCA serum 89, anti-FANCG83–622, anti-FANCF1–374, and anti-FANCE to visualize FANCA, FANCG, FANCF, and FANCE,
respectively. The asterisks indicate the position of FANCG. B, EUFA698 cells were stably transfected with cDNAs encoding the FANCF mutant
F1–15del-FLAG and wild-type FANCF-FLAG in expression vector pIRESneo. Immunoprecipitation was performed with anti-FLAG resin and
immunoprecipitated FA proteins were visualized by immunoblotting with anti-FANCA serum 89, anti-FANCC106–558, anti-FANCE, and anti-
FANCF1–374. C, mammalian two-hybrid assay indicating a lack of direct interaction between FANCF and FANCC or FANCE. Fold induction is
expressed relative to the luciferase activity obtained with empty vectors (pM and pVP16). D, mammalian three-hybrid assay illustrating the
interaction of FANCF and FANCF mutants with the FANCC/FANCE subcomplex. Fold induction is expressed relative to the luciferase activity
obtained with the pVP16-AD-FANCE vector alone. Results shown are mean  S.D. and derived from an experiment in triplicate.
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(R10AF11A) had a reduced biological activity, but only in com-
bination with a C-terminal deletion of 31 amino acids (Fig. 9B). A
possible explanation for the partial inactivation of the protein is
the prediction of a similar -helix (amino acids 31–48), in which
a conserved arginine (Arg-47) and phenylalanine (Phe-48) are
found (Fig. 7). These amino acids might be able to partially
compensate for the amino acid changes in the first -helix. To
test this hypothesis, we constructed a mutant in which the argin-
ines and phenylalanines in both helices were replaced by ala-
nines (R10AF11AR47AF48A). When combined with a dele-
tion of the C terminus, this mutant was totally inactive (Fig. 9B).
A mutant in which only Arg-47 and Phe-48 were changed
(R47AF48A) was functional (Fig. 9B). These results indicate
that the conserved arginines (Arg-10 and Arg-47) and phenylala-
FIG. 7. The N terminus of FANCF contains two amphipathic -helices. Sequence alignment showing the homology between the N terminus
of human and X. laevis FANCF. Two amphipathic -helices were predicted by Jpred and DNAsis software. The arrows indicate the hydrophobic
moment of the helices. The functionally important amino acids are in bold and underlined. Asterisks (*) indicate the serine-threonine stretch.
TABLE II
Activity of the FANCF mutants in different assays
Mutants in bold are not complementing MMC sensitivity.
FANCF mutant MMC test FANCA interaction (IP) MMC test upon removalof the C terminus FANCC/FANCE interaction (M3H)
delC31 a b nac 2d
1–15del  2 nde 
Q6A    nd
D9A  R10A  nd  nd
R10A    nd
R10E    nd
F11A    nd
F11Y    nd
R10A  F11A   2 
F11A  E13A   2 nd
R47A  F48A    nd
R10A  F11A  R47A  F48A  nd  
E2A  D9A  E13A    nd
E2K  D9K  E13K  2  nd
L5A  L8A  L15A  2  
L8P  nd  nd
L14P  nd  nd
L14A    nd
L41P    nd
L8P  L41P  nd nd nd
L14P  L41P  nd nd nd
S18A    
S18A  S19A  T20A  T21A    
a , normal activity.
b , no activity.
c na, not applicable.
d2, reduced activity.
e nd, not determined.
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nines (Phe-11 and Phe-48) in the first and second -helix may
form a functional unit. The M3H assay was used to show that the
R10AF11AR47AF48A mutant (with an intact C terminus)
was unable to interact with the FANCC/FANCE subcomplex
(Fig. 9C), suggesting that these arginine and phenylalanine res-
idues participate in this direct interaction.
In order to investigate whether the two predicted N-terminal
-helices are really being formed and function as a unit, several
leucine to proline mutants were made to disrupt the helical
structure of this region (Table II). The disruption of the first
-helix by substitution of Leu-8 or Leu-14 as well as the dis-
ruption of the second -helix by substitution of Leu-41 inter-
fered with the biological activity of the protein, but again only
when the C-terminal 31 amino acids were removed. As a con-
trol, we replaced Leu-14 by alanine and deleted its C terminus,
and found that this did not affect the function of the protein.
These results imply that the two N-terminal -helices in
FANCF form a functionally important structure, which coop-
erates with the C terminus of the protein.
A serine and threonine stretch (Ser-18, Ser-19, Thr-20, Thr-
21) is located just after the first N-terminal -helix. To inves-
tigate the functional significance of this region we changed
these amino acids into alanines. This mutant was again inac-
tive after removal of its C terminus (Fig. 9D). However, a
mutant (S18A) in which only the conserved Ser-18 was changed
to an alanine appeared to be functional (Fig. 9D). Subsequent
analysis of these FANCF mutants (with an intact C terminus)
in the M3H assay showed that only the mutant S18A was able
to activate the luciferase reporter gene (Fig. 9E). These data
suggest that the serine and threonine stretch is of functional
importance and is involved in the binding of the FANCC/
FANCE subcomplex.
Amino Acids 76–84 Are Not Essential for the Function of
FANCF—FA-F patient EUFA698 has a 23-bp deletion in the
FANCF gene resulting in a frameshift at codon 77 (5). Since the
deleted region is poorly conserved between human and Xeno-
pus FANCF, we tried to overcome the defect by selection for a
phenotypic revertant in vitro. After long term culture of a
lymphoblastoid cell line from patient EUFA698 in the presence
of 15 nM MMC an MMC-resistant cell line was obtained. Se-
quence analysis indicated that a deletion of nucleotide 225
(225delT) had restored the FANCF reading frame in one allele
of the reverted cell line (Fig. 10). In the mutant protein, Pro-76
is changed into a glutamine whereas amino acids 77–84 are
absent. This FANCF mutant is expressed and has a normal
interaction with FANCA (Fig. 10). These data therefore indi-
cate that amino acids 76–84 are not essential for the comple-
menting activity of the FANCF protein and support the idea
that the structure of FANCF is rather flexible.
DISCUSSION
Highly conserved amino acids are generally thought to be
critical for a protein’s function. By using an extensive site-
directed mutagenesis approach we have investigated the func-
tional importance of amino acids that are conserved between
human and X. laevis FANCF. Our results demonstrate that the C
terminus of FANCF binds directly to FANCG and is required for
stable interaction with FANCA, FANCC, and FANCE. Further-
FIG. 8. The negatively charged amino acids in the first N-terminal -helix of FANCF have an important function. A, MMC
hypersensitive phenotype of the FA-F cell line EUFA698 is corrected after stable transfection of cDNAs encoding FANCF mutants in which the
negatively charged amino acids Glu-2, Asp-9, and Glu-13 were mutated. Lymphoblastoid cell line HSC93 is shown as a wild-type control. B, cell
lysates from FA-F lymphoblasts (EUFA698) and FA-F lymphoblasts stably transfected with the indicated FANCF mutants were immunoprecipi-
tated with guinea pig anti-FANCF1–245 and immunoblotted with rabbit FANCA antiserum 89 and rabbit anti-FANCF1–374 to show the interaction
between the different FANCF mutants and FANCA. C, deletion of 23 amino acids from the FANCF mutants in which the negatively charged amino
acids were mutated does only affect the ability of the E2KD9KE13K mutant to complement the MMC hypersensitive phenotype of the FA-F
cell line EUFA698. D, FANCF mutants in which the negatively charged amino acids were mutated are unable to complement the MMC
hypersensitive phenotype of the FA-F cell line EUFA698 upon removal of the C-terminal 31 amino acids.
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more, we found that the N terminus of FANCF is essential for the
direct interaction with the FANCC/FANCE subcomplex, and is
important for stabilizing the complex formation with FANCA
and FANCG. This study shows that FANCF is an adaptor pro-
tein, which keeps the other components of the FA core complex
together in such a way that they can perform their function.
A direct interaction between FANCF and FANCG has been
demonstrated using the yeast two-hybrid system (15) and the
C terminus of FANCF (amino acids 243–374) was shown to be
essential for this interaction (38). In the current study, we
found that the interaction site is specifically located in the
strongly conserved last 31 amino acids (amino acids 343–374)
of FANCF and that this particular region provides stability to
the FA core complex. Surprisingly, the C-terminal deletion
mutants were still able to complement the MMC hypersensi-
tivity of FA-F cells and to support the monoubiquitination of
FANCD2. The ability of the FANCFdelC31 mutant to com-
plement FA-F cells was not a result of overexpression of this
protein, since low expression levels of this mutant protein by
a leaky inducible vector (pMEP4) or by stable integration
(pIRESneo) still corrected the MMC hypersensitivity.2 Since
the mutant FANCFdelC31 also corrects the MMC hypersen-
sitivity of FA-F patient cell line EUFA1228,2 the comple-
menting activity of this mutant is also not cell line-depend-
ent. We infer from our results that the FANCFdelC31 mutant
protein has a reduced affinity for the other members of the
complex, undetectable in co-immunoprecipitation experi-
ments because of the stringent conditions of this assay, but
sufficient for a functional FA pathway. This conclusion is
supported by our data showing an interaction between the
FANCFdelC31 mutant and the FANCC/FANCE subcomplex
in the mammalian three-hybrid assay, which was undetect-
able in co-immunoprecipitation experiments.
The first 15 amino acids of FANCF are predicted to form an
-helix sharing 60% homology with Xenopus FANCF. This
region is essential for the function of FANCF, since a FANCF
mutant in which these amino acids were deleted failed to
correct the MMC hypersensitivity of EUFA698 cells. This
FANCF mutant appeared to have a normal nuclear localization
and a reduced interaction with FANCA and FANCG, indicating
that this particular region in FANCF is not directly involved in
the nuclear targeting of FANCF, but crucial for the stable
binding to FANCA and FANCG. Interestingly, the FANCF
mutant 1–15del failed to co-precipitate with FANCC and
FANCE, suggesting that this particular N-terminal region in
FANCF is required for the presence of FANCC and FANCE
within the FA core complex. The mammalian three-hybrid
system confirms this finding and provides strong evidence for
direct interaction between the first 15 amino acids of FANCF
and the FANCC/FANCE subcomplex.2 J. P. de Winter, unpublished data.
FIG. 9. Other functional important amino acids in the N terminus of FANCF. A, FANCF mutant in which Leu-5, Leu-8, and Leu-15 are
changed into alanines is not able to complement the MMC hypersensitive phenotype of EUFA698 cells after removal of the C-terminal 31 amino
acids. B, effect of arginine and phenylalanine substitutions in FANCF on the ability to complement the MMC hypersensitive phenotype of
EUFA698 cells. FANCF mutants R10AF11A and R10AF11AR47AR48A are inactivated upon removal of the C terminus. C, mammalian
three-hybrid assay illustrating the disturbed interaction between the FANCF mutants 3xL (L5AL8AL15A) and 2xRF
(R10AF11AR47AR48A) and the FANCC/FANCE subcomplex. Results shown are mean  S.D. and derived from an experiment in triplicate.
Fold induction is expressed relative to the luciferase activity obtained with the pVP16-AD-FANCE vector alone. D, FANCF mutant in which Ser-18,
Ser19, Thr-20, and Thr-21 are changed into alanine is not able to complement the MMC hypersensitive phenotype of EUFA698 cells after removal
of the C-terminal 31 amino acids. E, mammalian three-hybrid assay showing interaction of the FANCC/FANCE subcomplex with wild-type FANCF
and FANCF mutant S18A, which is lost in the FANCF mutant S18A/S19A/T20A/T21A (SSTT/A).
FANCF Is a Flexible Adaptor Protein39428
 at Vrije Universiteit, Medical Library, on December 21, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
To identify functionally relevant residues in the N terminus
of FANCF, we generated several mutations in the first 48
amino acids that contain two predicted -helices. Surprisingly,
we could not obtain inactive or partially functional mutants
without the additional removal of the last 31 amino acids when
we assayed for the ability to complement the MMC hypersen-
sitive phenotype of FA-F cells. This implies that the FANCA-
FANCG interaction needs to be disturbed before amino acid
substitutions in the N terminus of FANCF show an effect in
this assay. However, when tested in the M3H assay, mutations
in the N terminus of FANCF were sufficient to interfere with
the binding of the FANCC/FANCE subcomplex. Apparently,
the binding of FANCA and FANCG to the C terminus of
FANCF stabilizes the interaction of factors that bind to the N
terminus of FANCF, in particular the FANCC/FANCE subcom-
plex. By removing the C terminus of the FANCF protein we
interfered with this stabilizing effect. In the mammalian three-
hybrid assay we do not need to interfere with the binding of the
FANCA/FANCG subcomplex, since in this assay FANCA and
FANCG are not present. What we have essentially tested in the
mammalian three hybrid assay and the MMC test with the
C-terminally truncated N-terminal mutants is the same; the
interaction with the FANCC/FANCE subcomplex in the ab-
sence of the FANCA/FANCG subcomplex. Accordingly, the re-
sults of both assays are the same. The detection of a weak
interaction between FANCA and FANCE (Ref. 16 and Fig. 6A)
and between FANCA and FANCC (14) in co-immunoprecipita-
tion experiments on lysates of FA-F cells indicates that these
FA proteins have some affinity for each other, but that these
interactions need to be stabilized by the presence of FANCF.
The results of our experiments suggest that binding of the
FANCC/FANCE subcomplex to the N terminus of FANCF (in
case of the C-terminal deletion mutants) or binding of the
FANCA/FANCG subcomplex to C terminus of FANCF (in case
of the N-terminal missense mutants) is sufficient to activate
the FA pathway.
From the non-functional mutants we identified four critical
regions defined by a group of residues essential for the proper
function of FANCF. One region consists of 3 consecutive nega-
tively charged residues (Glu-2, Asp-9, Glu-13) located at one
side of the first -helix. It is tempting to speculate that this
region interacts through salt bridges with the 3 positively
charged residues (Arg-32, Arg-39, Arg-46) located at one side of
the second -helix to form a functional domain. Another impor-
tant region involves 3 conserved hydrophobic amino acids on
one side of the first -helix (Leu-5, Leu-8, Leu-15), which ap-
pear to form a binding site for the FANCC/FANCE subcomplex.
The conserved arginines (Arg-10 and Arg-47) and phenylala-
nines (Phe-11 and Phe-48) in the first and second -helix form
the third critical region in the N terminus of FANCF. These 4
residues combined are also involved in the association with the
FANCC/FANCE subcomplex and may either be a part of the
interaction domain or stabilize this domain. A fourth critical
region in the FANCF protein is formed by a stretch of serine-
threonine residues in the loop region between the two -helices.
Although there is no evidence as yet for post-translational
modification of FANCF, this specific region could be the target
for phosphorylation by a serine/threonine kinase. Alterna-
tively, these serines and threonines might be involved in pro-
tein-protein interaction through the formation of hydrogen
bonds. Our data show that this particular region plays a role in
the direct interaction with the FANCC/FANCE subcomplex.
Finally, the FANCF region homologous to the prokaryotic RNA
binding protein ROM (amino acid residues 145–209) does not
seem to have an essential ROM-like function. The FANCF
mutants R172A, E172P, and R173A (equivalent in ROM to
amino acids Q24 and R25, respectively) did not affect the func-
tion of FANCF.
We realize that these mutagenesis studies need to be inter-
preted with caution, because of the risk to affect the general
structure of the protein. However, since amino acid changes in
the N terminus and even deletions of the C terminus of FANCF
were tolerated, the FANCF structure seems to be very stable
and flexible. Also the fact that a deletion of the C terminus only
inactivates a subset of the N-terminal FANCF mutants indi-
cates that it is very difficult to affect the structure of the
FANCF protein. Consistent with this idea is that none of the
identified FA-F patients have missense mutations in FANCF,
but rather have nonsense mutations or deletions (5). Further-
more, an in vitro revertant of EUFA698 cells expresses a mu-
tant FANCF protein that lacks amino acids 76–84, which is
still functional. The only mutation that might have changed
the stucture of the FANCF protein is the N-terminal deletion
mutant, since this is the only single mutant that is unable to
restore the MMC hypersensitivity of FA-F cells.
Our results suggest a sequential recruitment of the FA gene
products in which the FANCF protein has a key role by linking
the different subcomplexes (FANCA/FANCG and FANCC/
FANCE) and possibly other components together. Therefore,
we propose that FANCF acts as an adaptor protein that plays
a key role in the proper assembly of the FA core complex. We
infer from our and published data that FANCF stabilizes the
interaction between the FANCC/FANCE subcomplex and the
FANCA/FANCG subcomplex and locks the whole FA core com-
plex in a conformation that is essential to perform its function.
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